



Project coordinator

Maurizio Bendandi

mbendandi@unav.es

Department of Hematology

Clínica Universidad de Navarra (CUN)

Pamplona (NAVARRA) | SPAIN

Design of novel anti-idiotypic vaccines adjuvanted with RNA-based nanoparticles: entry into nanotechnology based personalized cancer immunotherapy.

Acronym

Nanovaxid

project partners

- Karl-Josef Kallen | CureVac | Tübingen | GERMANY
- Jan Walewski | Department of Lymphoid Malignancies | Maria Skłodowska-Curie Memorial Institute and Oncology Centre | Warszawa | POLAND

Abstract

Follicular lymphoma is an indolent and yet incurable malignancy. Idiotypic vaccination is an experimental strategy designed to prevent disease relapse after mild chemotherapy by instructing the patient's own immune system to recognize and eliminate residual tumor cells. Currently, idiotypic vaccination succeeds in no more than half of the patients. In this study, we plan to replace the adjuvant molecules of the old formulation with a single, powerful, RN-nano-adjuvant, which will be evaluated both at the preclinical and clinical level.

